Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Belumosudil mesylate |
Synonyms | |
Therapy Description |
Rezurock (belumosudil mesylate) is a ROCK1/2 inhibitor that potentially induces tumor cell killing and decreases tumor growth (Blood (2023) 142 (Supplement 1): 651). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Belumosudil mesylate | Rezurock | KD025 mesylate|SLx-2119 mesylate|belumosudil | Rezurock (belumosudil mesylate) is a ROCK1/2 inhibitor that potentially induces tumor cell killing and decreases tumor growth (Blood (2023) 142 (Supplement 1): 651). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06105554 | Phase Ib/II | Belumosudil mesylate | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |